Vandria, a Lausanne, Switzerland-based mitochondrial therapeutics company, raised an undisclosed amount in its second Series A funding.
The round, which brought the total amount to $30.7M, saw participation from Hevolution Foundation and Dolby Family Ventures joined ND Capital.
The company intends to use the funds to expand operations and its development efforts.
Led by Klaus Dugi, CEO, Vandria is a mitochondrial therapeutics company, developing mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases. Its lead program, VNA-318, is a brain-penetrant, patent-protected, mitophagy inducer which has been shown to acutely improve memory and learning and to have disease-modifying effects in models of neurodegenerative disease such as Alzheimer’s and Parkinson’s disease. VNA-318 is expected to enter the clinic in 2024.
The company is also developing mitophagy-inducing small molecules to address muscle, lung, and liver diseases. A separate program targets ferroptosis, a form of cell death implicated in neurodegenerative diseases and ischemia reperfusion injury.
FinSMEs
21/08/2024